Drug intelligence / Profile preview

BI 1839100

Development stage: Discontinued
Lead developer: Boehringer
Modality: Small Molecules
Administration: Oral

Overview

BI 1839100 is an investigational oral small molecule drug developed by Boehringer Ingelheim for the treatment of pulmonary fibrosis, specifically idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The drug is currently in phase II clinical trials to evaluate its efficacy and safety in reducing chronic cough associated with these conditions. While the precise mechanism of action has not been disclosed, it is classified as an antifibrotic agent. Clinical studies focus on measuring reductions in cough frequency and improvements in lung function among affected patients[1][2][3][4][5].

Targets

TRPA1 (Transient receptor potential cation channel subfamily A member 1)

Beyond the preview

Go deeper on BI 1839100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 1839100.

Explore the full profile